Royalty Pharma plc

RPRX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders6.5%

Institutions87.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2013-12-31	2012-12-31	2011-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$2.38B	$2.26B	$2.35B	$2.24B	$2.29B	$2.12B	$9000	$3000	$48.01M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$1.56B	$1.29B	$1.49B	$307.06M	$1.43B	$1.60B	–	–	–
Operating income as a percentage of revenue.	65.6%	57.1%	63.4%	13.7%	62.5%	75.2%	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$553.25M	$471.83M	$565.25M	$187.23M	$621.47M	$726.91M	-$27.72M	-$18.17M	-$191.74M
Net income divided by the number of shares outstanding — profit attributable to each share.	$1.79	$1.92	$2.54	$0.10	$1.49	$1.32	$-1.33	$-1.18	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$1.78	$1.91	$2.53	$0.10	$1.49	$1.32	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2013-12-31	2012-12-31	2011-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$618.70M	$929.03M	$477.01M	$1.71B	$1.54B	$1.01B	$75.81M	$24.21M	$4.57M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$19.62B	$18.22B	$16.38B	$16.81B	$17.52B	$16.02B	–	–	–
All of the company's interest-bearing borrowings, short and long term combined.	$8.95B	$7.61B	$6.14B	$7.12B	$7.10B	$5.82B	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$9.91B	$7.88B	$6.30B	$7.29B	$7.27B	$6.12B	–	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$9.71B	$10.34B	$10.08B	$9.53B	$10.25B	$9.90B	–	–	–

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2013-12-31	2012-12-31	2011-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$2.49B	$2.77B	$2.99B	$2.14B	$2.02B	$2.03B	-$24.45M	-$13.49M	-$168.41M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	–	–	–	$63000	$30000	$2.39M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	–	–	–	-$24.51M	-$13.53M	-$170.80M

	You	Peer avg
P/E	34.4	57.1
Revenue Growth	+16.5%	+15.5%
ROE	14.0%	35.0%

Royalty Pharma plc

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison